SG11201906318WA - Algorithms and methods for assessing late clinical endpoints in prostate cancer - Google Patents
Algorithms and methods for assessing late clinical endpoints in prostate cancerInfo
- Publication number
- SG11201906318WA SG11201906318WA SG11201906318WA SG11201906318WA SG11201906318WA SG 11201906318W A SG11201906318W A SG 11201906318WA SG 11201906318W A SG11201906318W A SG 11201906318WA SG 11201906318W A SG11201906318W A SG 11201906318WA SG 11201906318W A SG11201906318W A SG 11201906318WA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- prostate cancer
- drive
- pct
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 5
- 238000004422 calculation algorithm Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 240000005020 Acaciella glauca Species 0.000 abstract 2
- 235000003499 redwood Nutrition 0.000 abstract 2
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Primary Health Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Image Processing (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, C12Q 1/6809 (2018.01) C12Q 1/6886 (2018.01) (21) International Application Number: PCT/US2018/017790 (22) International Filing Date: KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (25) Filing Language: (26) Publication Language: (30) Priority Data: 12 February 2018 (12.02.2018) English English 62/458,474 13 February 2017 (13.02.2017) US 62/473,204 17 March 2017 (17.03.2017) US 62/578,622 30 October 2017 (30.10.2017) US (71) Applicant: GENOMIC HEALTH, INC. [US/US]; 301 Penobscot Drive, Redwood City, California 94063 (US). (72) Inventors: LU, Ruixiao; 301 Penobscot Drive, Redwood City, California 94063 (US). CRAGER, Michael; 301 Penobscot Drive, Redwood City, California 94063 (US). ZHANG, Nan; 3234 Mountain Drive, Fremont, California 94555 (US). MADDALA, Tara; 1166 Ribier Court, Sun- nyvale, California 94087 (US). FEBBO, Phillip; 14 Glen Drive, Mill Valley, California 94941 (US). LAWRENCE, Hugh Jeffrey; 6221 Contra Costa Road, Oakland, Califor- nia 94618 (US). (74) Agent: DOHERTY, Elizabeth et al.; McNeill Baur PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massa- chusetts 02140 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, cc (54) Title: ALGORITHMS AND METHODS FOR ASSESSING LATE CLINICAL ENDPOINTS IN PROSTATE CANCER 00 (57) : The present disclosure relates to uses of a multiple gene-expression based Genomic Prostate Score TM (GPS TM ) algo- rithm for assessment of various clinical endpoints in prostate cancer patients, such as risks of clinical recurrence (CR), biochemical O recurrence (BCR), distant metastasis (Mets), and prostate cancer death (PCD). In some embodiments, GPS result is determined for low C and intermediate risk prostate cancer patients in order to assist in determining treatment strategies for those patients. °Ens °nolo olommoiloo mil oimIE (10) International Publication Number WO 2018/148642 Al
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458474P | 2017-02-13 | 2017-02-13 | |
| US201762473204P | 2017-03-17 | 2017-03-17 | |
| US201762578622P | 2017-10-30 | 2017-10-30 | |
| PCT/US2018/017790 WO2018148642A1 (en) | 2017-02-13 | 2018-02-12 | Algorithms and methods for assessing late clinical endpoints in prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906318WA true SG11201906318WA (en) | 2019-08-27 |
Family
ID=61283339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912097QA SG10201912097QA (en) | 2017-02-13 | 2018-02-12 | Algorithms and methods for assessing late clinical endpoints in prostate cancer |
| SG11201906318WA SG11201906318WA (en) | 2017-02-13 | 2018-02-12 | Algorithms and methods for assessing late clinical endpoints in prostate cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912097QA SG10201912097QA (en) | 2017-02-13 | 2018-02-12 | Algorithms and methods for assessing late clinical endpoints in prostate cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200040400A1 (en) |
| EP (1) | EP3580357B1 (en) |
| JP (1) | JP7239477B2 (en) |
| KR (1) | KR102376220B1 (en) |
| CN (1) | CN110291206A (en) |
| AU (1) | AU2018219354B2 (en) |
| BR (1) | BR112019016652A2 (en) |
| CA (1) | CA3049844C (en) |
| CO (1) | CO2019008649A2 (en) |
| ES (1) | ES2914727T3 (en) |
| IL (1) | IL267911B2 (en) |
| MX (1) | MX2019009027A (en) |
| SG (2) | SG10201912097QA (en) |
| WO (1) | WO2018148642A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019221930A1 (en) * | 2018-05-16 | 2019-11-21 | Opko Diagnostics, Llc | Methods for detecting prostate cancer pathology associated with adverse outcomes |
| CN109306867B (en) * | 2018-11-19 | 2022-04-05 | 中国石油天然气股份有限公司 | Method for automatically identifying alluvial fan sedimentary reservoir configuration unit |
| CN115427811A (en) * | 2020-04-23 | 2022-12-02 | 日兴生物科技有限公司 | Methods relating to prostate cancer diagnosis |
| KR102497196B1 (en) | 2020-09-08 | 2023-02-07 | (주)유로테크 | A method to calculate a diagnostic score for a prostate cancer and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7587279B2 (en) | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
| US20080275652A1 (en) * | 2005-05-13 | 2008-11-06 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
| ES2373686T3 (en) | 2005-06-23 | 2012-02-07 | Biocartis Sa | CARTRIDGE, SYSTEM AND PROCEDURE FOR AUTOMATED MEDICAL DIAGNOSTICS. |
| EP2407554A1 (en) * | 2010-07-14 | 2012-01-18 | Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron | Methods and kits for the diagnosis of prostate cancer |
| EP2809812A4 (en) | 2012-01-31 | 2016-01-27 | Genomic Health Inc | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| US9200328B1 (en) * | 2012-03-14 | 2015-12-01 | New York University | Methods and kits for diagnosing the prognosis of cancer patients |
| DK3303618T3 (en) * | 2015-05-29 | 2019-12-16 | Koninklijke Philips Nv | PROCEDURES FOR PROJECTING PROSTATANCES |
-
2018
- 2018-02-12 ES ES18707504T patent/ES2914727T3/en active Active
- 2018-02-12 KR KR1020197023192A patent/KR102376220B1/en active IP Right Grant
- 2018-02-12 CA CA3049844A patent/CA3049844C/en active Active
- 2018-02-12 JP JP2019542696A patent/JP7239477B2/en active Active
- 2018-02-12 CN CN201880011757.7A patent/CN110291206A/en active Pending
- 2018-02-12 SG SG10201912097QA patent/SG10201912097QA/en unknown
- 2018-02-12 BR BR112019016652-1A patent/BR112019016652A2/en unknown
- 2018-02-12 MX MX2019009027A patent/MX2019009027A/en unknown
- 2018-02-12 EP EP18707504.9A patent/EP3580357B1/en active Active
- 2018-02-12 WO PCT/US2018/017790 patent/WO2018148642A1/en active Application Filing
- 2018-02-12 SG SG11201906318WA patent/SG11201906318WA/en unknown
- 2018-02-12 AU AU2018219354A patent/AU2018219354B2/en active Active
- 2018-02-12 US US16/485,203 patent/US20200040400A1/en active Pending
-
2019
- 2019-07-08 IL IL267911A patent/IL267911B2/en unknown
- 2019-08-09 CO CO2019008649A patent/CO2019008649A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3049844A1 (en) | 2018-08-16 |
| SG10201912097QA (en) | 2020-02-27 |
| MX2019009027A (en) | 2020-01-27 |
| US20200040400A1 (en) | 2020-02-06 |
| JP2020507320A (en) | 2020-03-12 |
| ES2914727T3 (en) | 2022-06-15 |
| CN110291206A (en) | 2019-09-27 |
| EP3580357B1 (en) | 2022-04-27 |
| IL267911B2 (en) | 2023-08-01 |
| JP7239477B2 (en) | 2023-03-14 |
| EP3580357A1 (en) | 2019-12-18 |
| WO2018148642A1 (en) | 2018-08-16 |
| BR112019016652A2 (en) | 2020-03-31 |
| AU2018219354B2 (en) | 2024-06-27 |
| KR20190113814A (en) | 2019-10-08 |
| CA3049844C (en) | 2022-06-28 |
| CO2019008649A2 (en) | 2019-10-31 |
| IL267911B1 (en) | 2023-04-01 |
| AU2018219354A1 (en) | 2019-07-25 |
| IL267911A (en) | 2019-09-26 |
| KR102376220B1 (en) | 2022-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201908564RA (en) | Devices, processes, and systems for determination of nucleic acid sequence, expression, copy number, or methylation changes using combined nuclease, ligase, polymerase, and sequencing reactions | |
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201906318WA (en) | Algorithms and methods for assessing late clinical endpoints in prostate cancer | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| SG11201901841TA (en) | Targeting ligands | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201908396PA (en) | Methods of treating tumor | |
| SG11201806861SA (en) | Combination therapy with anti-cd73 antibodies | |
| SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
| SG11201805157TA (en) | Targeted disruption of the mhc cell receptor | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201901628XA (en) | Methods and compositions for spinal cord cells | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201408787PA (en) | Enhancing activity of car t cells by co-introducing a bispecific antibody | |
| SG11201806432PA (en) | Methods for assessing risk of developing colorectal cancer | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells | |
| SG11201907607VA (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
| SG11201408434QA (en) | Targeted rna-seq methods and materials for the diagnosis of prostate cancer |